Article
Oncology
Christoforos K. Vaxevanis, Michael Friedrich, Sandy Uta Tretbar, Diana Handke, Yuan Wang, Juliane Bluemke, Reinhard Dummer, Chiara Massa, Barbara Seliger
Summary: This study revealed a novel mechanism in which miRNAs targeting the coding sequence of immune checkpoint genes are functional and have prognostic relevance. It also has the potential for the development of novel miRNA-based therapies.
CLINICAL AND TRANSLATIONAL MEDICINE
(2022)
Article
Oncology
Richard S. P. Huang, Brennan Decker, Karthikeyan Murugesan, Matthew Hiemenz, Douglas A. Mata, Gerald Li, James Creeden, Shakti H. Ramkissoon, Jeffrey S. Ross
Summary: The study found low prevalence of non-amplification short variants (SV) mutations in CD274, with mutation types and rates varying by tumor type. Specific mutation types may affect the expression level of PD-L1 protein and potentially function as resistance biomarkers in ICPI therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Andrew D. Kelly, Karthikeyan Murugesan, Zheng Kuang, Meagan Montesion, Jeffrey S. Ross, Lee A. Albacker, Richard S. P. Huang, Douglas Lin, Umut Demirci, James Creeden
Summary: CD274 gene rearrangements are associated with increased PD-L1 immunohistochemistry scores, higher tumor mutational burden, and potential clinical benefit in patients with cancer receiving ICI treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Richard S. P. Huang, Karthikeyan Murugesan, Meagan Montesion, Dean C. Pavlick, Douglas A. Mata, Matthew C. Hiemenz, Brennan Decker, Garrett Frampton, Lee A. Albacker, Jeffrey S. Ross
Summary: The study analyzed a large cohort of solid tumor cases to investigate CD274 copy-number changes and their correlation with PD-L1 protein expression. The prevalence of CD274 copy-number changes varied across different tumor types and was found to be significantly associated with PD-L1 positivity in certain tumor types, indicating its potential as a biomarker for immune checkpoint inhibitor therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Hanna Elomaa, Maarit Ahtiainen, Sara A. Vaeyrynen, Shuji Ogino, Jonathan A. Nowak, Mai Chan Lau, Olli Helminen, Erkki-Ville Wirta, Toni T. Seppaelae, Jan Boehm, Jukka-Pekka Mecklin, Teijo Kuopio, Juha P. Vaeyrynen
Summary: The expression patterns and prognostic significance of PD-L1 and PD-1 in the colorectal cancer microenvironment are inadequately characterised. This study found that PD-L1(+) macrophages and PD-1(+) T cells were associated with better clinical outcomes in colorectal cancer patients. These findings enhance the understanding of immune checkpoints in the tumor microenvironment and could contribute to the development of improved immunotherapies.
BRITISH JOURNAL OF CANCER
(2023)
Article
Immunology
Mohamed I. Sakran, Adel I. Alalawy, Amnah A. Alharbi, Mohamed E. El-Hefnawy, Salem M. Alzahrani, Ahmed Alfuraydi, Fahad Mohammed Alzuaibr, Nahla S. Zidan, Afaf M. Elsaid, Eman A. Toraih, Rami M. Elshazli
Summary: This study identified novel associations between PD-L1/CD274 polymorphisms and susceptibility to lung cancer in Egyptians, with the rs2297136 variant increasing risk and the rs4143815 variant conferring protection. These findings highlight the importance of the PD-1/PD-L1 axis as a potential biomarker and therapeutic target in lung oncogenesis.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Hikaru Nanamori, Yu Sawada
Summary: Malignant melanoma is a skin cancer with unfavorable clinical behavior, and immunotherapy is currently used for treatment. However, not all patients can benefit from this therapy. To overcome this limitation, clinicians have focused on epigenetic modification, which may have additional therapeutic efficacy by regulating gene expression.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Chemistry, Multidisciplinary
Yuedi Yang, Yani Cui, Wanxu Cao, Mingda Zhao, Weimin Lin, Ruiling Xu, Yang Xu, Yafang Chen, Hongjun Li, Jie Liang, Yunfeng Lin, Yujiang Fan, Xingdong Zhang, Yong Sun
Summary: By injecting short rod-like nanohydroxyapatite, the upregulation of PD-L1 related gene transcription can be enhanced, leading to improved immune response. Based on this, researchers developed an injectable hydrogel reservoir for combination immunotherapy, which showed significant therapeutic effects.
Article
Oncology
Lin Yang, Shousheng Liu, Wenzhuo He, Zhenchong Xiong, Liangping Xia
Summary: This study evaluated PD-L1 genetic alterations in patients with colorectal cancer (CRC) and analyzed their correlation with tumor immune microenvironment and clinical implications. The prevalence of PD-L1 genetic alterations was relatively low in CRC, but they were associated with aggressive features. The correlation between PD-L1 genetic alterations and tumor immune features was only observed in mismatch repair-deficient (dMMR) CRC.
Article
Immunology
Chun-Yi Lai, Po-Chun Tseng, Chia-Ling Chen, Rahmat Dani Satria, Yung-Ting Wang, Chiou-Feng Lin
Summary: This study demonstrated increased expression of CD11b and CD68, as well as PD-L1/PD-1, in PMA-induced THP-1-differentiated macrophages, indicating a potential role in immune response. Furthermore, the neutralization of PD-L1/PD-1 did not impact THP-1 cell differentiation or macrophage polarization.
JOURNAL OF INFLAMMATION RESEARCH
(2021)
Article
Medicine, Research & Experimental
Lin Zhao, Wenxin Zhang, Fengming Luan, Xi Chen, Honghai Wu, Qiaojun He, Qinjie Weng, Ling Ding, Bo Yang
Summary: PD-L1 plays a critical role in tumor immune escape and can be targeted by blocking antibodies or suppressing its expression. Butein, a natural compound, has been shown to reduce PD-L1 expression and enhance the killing ability of CD8+ T cells, offering a potential strategy for anti-tumor therapy.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Engineering, Chemical
Rui Wang, Nan Ni, Qi-xian Zhang, Xu-lin Duan, Qiang He, Yuan-long Chi
Summary: Flavonoid aglycones and flavonol aglycones, such as apigenin and kaempferol, were successfully separated using a Zr(IV) immobilized collagen fiber (ZCF). The adsorption capacity of ZCF for kaempferol was higher than apigenin, and efficient separation of flavonol aglycones from flavonoid aglycones was achieved through ZCF column chromatography.
SEPARATION AND PURIFICATION TECHNOLOGY
(2022)
Article
Medicine, Research & Experimental
Zhen-zhen Zhao, Xiao-lin Wang, Jian Xie, Li-ping Chen, Qian Li, Xiao-xiao Wang, Jia-feng Wang, Xiao-ming Deng
Summary: The study showed that KN035 has therapeutic effects in septic mice, improving survival rates and reducing apoptosis in the spleen. KN035 also alleviated lung and liver damage, decreased the number of apoptotic cells in the spleen, and helped eliminate bacteria in the peritoneal cavity.
MEDICAL SCIENCE MONITOR
(2021)
Article
Oncology
Xisha Chen, Kuansong Wang, Shilong Jiang, Hongyin Sun, Xuanling Che, Minghui Zhang, Jiaying He, Ying Wen, Mengting Liao, Xiangling Li, Xiaoming Zhou, Jianxun Song, Xingcong Ren, Wenjun Yi, Jinming Yang, Xiang Chen, Mingzhu Yin, Yan Cheng
Summary: Our study reveals that eEF2K is correlated with therapeutic response and prognosis in melanoma patients treated with anti-PD-1 therapy. We also show that eEF2K plays a vital role in regulating the tumor immune microenvironment by controlling PD-L1 expression. In addition, combining eEF2K inhibition with ICB therapy may provide a potential combination therapeutic strategy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Niklas Kluemper, Lennert Wuest, Jonas Saal, Damian J. Ralser, Romina Zarbl, Jonas Jarczyk, Johannes Breyer, Danijel Sikic, Bernd Wullich, Christian Bolenz, Florian Roghmann, Michael Hoelzel, Manuel Ritter, Sebastian Strieth, Arndt Hartmann, Philipp Erben, Ralph M. Wirtz, Jennifer Landsberg, Dimo Dietrich, Markus Eckstein
Summary: This study evaluated the predictive potential of PD-L1 promoter methylation status in immune checkpoint blockade (ICB) treatment of metastatic urothelial carcinoma (mUC). The study found that hypomethylation of the PD-L1 promoter is a promising predictive biomarker for response to ICB in patients with mUC, while PD-L1 protein expression status is not correlated with treatment response and survival.
Article
Cell Biology
Taishu Wang, Jinrui Zhang, Shanshan Wang, Xiuna Sung, Duchuang Wang, Yurou Gao, Yang Zhang, Lu Xu, Yue Wu, Yueguang Wu, Fang Liu, Xiuxiu Liu, Shuyan Liu, Yingqiu Zhang, Yang Wang, Lijuan Zou, Han Liu
CELL COMMUNICATION AND SIGNALING
(2018)
Article
Cell Biology
Jinrui Zhang, Qiong Li, Yueguang Wu, Duchuang Wang, Lu Xu, Yang Zhang, Shanshan Wang, Taishu Wang, Fang Liu, Mohamed Y. Zaky, Shuai Hou, Shuyan Liu, Kun Zou, Haixin Lei, Lijuan Zou, Yingqiu Zhang, Han Liu
CELL COMMUNICATION AND SIGNALING
(2019)
Article
Biochemistry & Molecular Biology
Mohamed Y. Zaky, Xiuxiu Liu, Taishu Wang, Shanshan Wang, Fang Liu, Duchuang Wang, Yueguang Wu, Yang Zhang, Dong Guo, Qianhui Sun, Qiong Li, Jinrui Zhang, Yingqiu Zhang, Weijie Dong, Zhenhua Liu, Shuyan Liu, Han Liu
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
(2020)
Article
Biochemistry & Molecular Biology
Jinrui Zhang, Shuyan Liu, Qiong Li, Yulin Shi, Yueguang Wu, Fang Liu, Shanshan Wang, Mohamed Y. Zaky, Waleed Yousuf, Qianhui Sun, Dong Guo, Taishu Wang, Yingqiu Zhang, Yang Wang, Man Li, Han Liu
CELL DEATH AND DIFFERENTIATION
(2020)
Review
Pharmacology & Pharmacy
Lu Xu, Mohamed Y. Zaky, Waleed Yousuf, Anwar Ullah, Gehad R. Abdelbaset, Yingqiu Zhang, Osama M. Ahmed, Shuyan Liu, Han Liu
Summary: Apigenin, an edible flavonoid widely distributed in natural plants, has been shown to possess anti-inflammatory, anti-oxidative, anti-bacterial, anti-viral, anti-tumor, and cardiovascular protective effects. Recent research has highlighted its potential anti-cancer roles through immunoregulatory functions. The immunoregulatory properties of apigenin in various diseases, especially neoplasms, are being recognized, suggesting a potential therapeutic role in cancer immunotherapy.
CURRENT PHARMACEUTICAL DESIGN
(2021)
Article
Cell Biology
Yueguang Wu, Yingqiu Zhang, Duchuang Wang, Yang Zhang, Jinrui Zhang, Yayun Zhang, Lu Xu, Taishu Wang, Shanshan Wang, Qingqing Zhang, Fang Liu, Mohamed Y. Zaky, Qiong Li, Qianhui Sun, Dong Guo, Shuyan Liu, Lijuan Zou, Qingkai Yang, Han Liu
CELL DEATH & DISEASE
(2020)
Review
Pharmacology & Pharmacy
Osama M. Ahmed, Sameh F. AbouZid, Noha A. Ahmed, Mohamed Y. Zaky, Han Liu
Summary: This article provides an overview of citrus flavonoids in fruits and their health benefits. It also discusses the mechanisms of actions of citrus flavonoids in the treatment of various diseases.
CURRENT PHARMACEUTICAL DESIGN
(2021)
Article
Biochemistry & Molecular Biology
Shuyan Liu, Taishu Wang, Yulin Shi, Lu Bai, Shanshan Wang, Dong Guo, Yang Zhang, Yangfan Qi, Chaoqun Chen, Jinrui Zhang, Yingqiu Zhang, Quentin Liu, Qingkai Yang, Yang Wang, Han Liu
Summary: Liquid-liquid phase separation is a generic approach to studying the dynamic regulation of phase-separated assemblies and the roles of protein posttranslational modifications. USP42, a deubiquitylase, has been identified to play a pivotal role in nuclear speckle phase separation, mRNA splicing, and cancer cell growth. Inhibition of USP42 presents a novel anticancer strategy by targeting phase separation.
CELL DEATH AND DIFFERENTIATION
(2021)
Article
Multidisciplinary Sciences
Qianhui Sun, Jinrui Zhang, Xiaoxi Li, Guoheng Yang, Shaoxuan Cheng, Dong Guo, Qingqing Zhang, Feng Sun, Feng Zhao, Dian Yang, Shanshan Wang, Taishu Wang, Shuyan Liu, Lijuan Zou, Yingqiu Zhang, Han Liu
Summary: Melatonin has anticancer effects in lung adenocarcinoma, and its receptor MT1 is downregulated by melatonin treatment, which is protected by the USP8-related endocytic pathway. Inhibiting USP8 can suppress the proliferation of lung adenocarcinoma cells and enhance the anticancer effects of melatonin.
JOURNAL OF ADVANCED RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Jinrui Zhang, Ge Zhang, Wenjing Zhang, Lu Bai, Luning Wang, Tiantian Li, Li Yan, Yang Xu, Dan Chen, Wenting Gao, Chuanzhou Gao, Chaoqun Chen, Menglin Ren, Yuexia Jiao, Hongqiang Qin, Yu Sun, Lili Zhi, Yangfan Qi, Jinyao Zhao, Quentin Liu, Han Liu, Yang Wang
Summary: The RNA binding protein RBMS1 is prevalent in immune-cold triple-negative breast cancers (TNBC) and plays a role in regulating the stability of programmed death ligand 1 (PD-L1). Depletion of RBMS1 enhances cytotoxic T cell mediated anti-tumor immunity and combination with immune checkpoint blockade or CAR-T treatment further enhances anti-tumor T-cell immunity. Our findings provide a new immunotherapeutic strategy targeting the immunosuppressive RBMS1 in TNBC.
CELL DEATH AND DIFFERENTIATION
(2022)
Article
Oncology
Shanshan Wang, Taishu Wang, Qianyi Yang, Shaoxuan Cheng, Fang Liu, Guoheng Yang, Fuqiang Wang, Ruilin Wang, Dian Yang, Mingyu Zhou, Chengen Duan, Yingqiu Zhang, Han Liu, Zhaoxia Dai, Kang Tian, Shuyan Liu
Summary: This study uncovers the important role of proteasomal deubiquitylases in the endocytic regulation of EGFR and shows that inhibition of deubiquitylase activity leads to increased ubiquitylation and accumulation of EGFR on recycling endosomes. The dual inhibitor b-AP15 exhibits potent tumor-suppressive effects in lung cancer cells.
Article
Multidisciplinary Sciences
Shuyan Liu, Yayun Zhang, Qianyi Yang, Yingqiu Zhang, Han Liu, Mu-Hua Huang, Ruoyu Wang, Faqiang Lu
Summary: This study discovered that a compound named BD-15 exerted anti-tumor effects by enhancing PKC signaling, resulting in cell growth inhibition, cell cycle arrest, upregulation and phosphorylation of p21, and induction of cellular apoptosis in non-small cell lung cancer.
Article
Biochemistry & Molecular Biology
Shanshan Wang, Taishu Wang, Xuehong Zhang, Shaoxuan Cheng, Chaoqun Chen, Guoheng Yang, Fuqiang Wang, Ruilin Wang, Qingqing Zhang, Dian Yang, Yingqiu Zhang, Shuyan Liu, Hongqiang Qin, Quentin Liu, Han Liu
Summary: This study reveals the tumor-promoting role of USP35 in renal clear cell carcinoma by maintaining NRF2 levels and protecting against apoptosis and ferroptosis.
CELL DEATH AND DIFFERENTIATION
(2023)
Article
Medicine, Research & Experimental
Wenjing Zhang, Yu Sun, Lu Bai, Lili Zhi, Yun Yang, Qingzhi Zhao, Chaoqun Chen, Yangfan Qi, Wenting Gao, Wenxia He, Luning Wang, Dan Chen, Shujun Fan, Huan Chen, Hai-Long Piao, Qinglong Qiao, Zhaochao Xu, Jinrui Zhang, Jinyao Zhao, Sirui Zhang, Yue Yin, Chao Peng, Xiaoling Li, Quentin Liu, Han Liu, Yang Wang
Summary: RBMS1 is a key regulator of ferroptosis in lung cancer development and its high expression is associated with reduced patient survival. Depletion or inhibition of RBMS1 can promote ferroptosis and sensitize radioresistant lung cancer cells to radiotherapy. RBMS1 interacts with eIF3d to regulate translation of SLC7A11, playing a critical role in ferroptosis evasion during lung cancer progression.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Biochemistry & Molecular Biology
Yuesheng Lv, Wenjing Zhang, Jinyao Zhao, Bing Sun, Yangfan Qi, Haoyu Ji, Chaoqun Chen, Jinrui Zhang, Junxiu Sheng, Taishu Wang, Daniel Dominguez, Han Liu, Quentin Liu, Songshu Meng, Xiaoling Li, Yang Wang
Summary: SRSF1 is identified as an autophagy suppressor that inhibits autophagosome formation by promoting the splicing of Bcl-x and disrupting the Beclin1-PIK3C3 complex. The decrease of SRSF1 stabilizes the Beclin1 and PIK3C3 complex, activating autophagy, while starvation- and oxidative stresses-induced autophagy can degrade SRSF1 through interacting with LC3-II. This positive feedback mechanism is crucial for inhibiting Gefitinib-resistant cancer cell progression.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2021)